Preclinical Models of Multiple Myeloma

“Preclinical Models of Multiple Myeloma” Introduction and Background Multiple myeloma is a clonal B cell malignancy characterized by the accumulation of terminally differentiated, antibody-producing plasma cells in the bone marrow that is invasive and drug resistant. Patients are generally asymptomatic until very late state disease. There are few preclinical models […]

MM.1S: A Model for Multiple Myeloma

Mean Total Tumor Burden BLI Signal In SCID beige mice, the median tumor volume doubling time is ~2 days (Figure 3), and median time to morbidity/mortality endpoint is 35-45 days. To further optimize the MM.1S-pMMP-LucNeo model, we characterized growth in the NSG mouse strain which shows more aggressive disease onset […]

C1498: A Murine Model for Acute Myelogenous Leukemia (AML)

Survival (morbidity/mortality) kinetics (Figure 2A) show a median survival of approximately 23 days; although, the mice show no body weight loss during the course of disease progression (Figure 2B). Survival Kinetics and Body Weight Change Fig. 2: Survival kinetics (A) and body weight change (B) of C57BL/6 mice with disseminated […]

PC-3M-Luc-C6 – A Model for Prostate Carcinoma

Orthotopic Modeling In an effort to address this unmet need, MI Bioresearch has developed an orthotopic and a metastatic prostate model, PC-3M-Luc-C6. This cell line has been transfected with luciferase, which allows for disease and response monitoring through bioluminescence imaging (BLI). The orthotopic model is implanted directly into the prostate […]

4T1-luc2: An Orthotopic Mammary Cancer Model to Support Novel Immuno-Oncology Drug Discovery

Breast cancer is the second most deadly malignancy after lung cancer in woman in the United States, with an estimated 246,000 new cases and 40,450 deaths expected in 2016. Many treatment options for breast cancer exist including surgery, radiotherapy, anti-estrogen therapy, targeted therapies (e.g., trastuzumab), and chemotherapy. Despite these therapeutic advances, metastatic disease remains a […]

786-O (pMMP-LucNeo) – A Model for Renal Cell Carcinoma

In an effort to address this unmet need, MI Bioresearch has developed an orthotopic RCC model, 786-O (pMMP-LucNeo) through implantation into the sub-renal capsule. This cell line has been transfected with luciferase, which allows for disease and response monitoring through bioluminescence imaging (BLI). In 786-O tumor bearing mice, we evaluated […]

5TGM1-luc – A Syngeneic Murine Model for Multiple Myeloma

The 5TGM1 multiple myeloma model arose spontaneously in aging C57BL/KaLwRij mice, and was propagated via serial passage in syngeneic mice prior to establishment of a cell line. MI Bioresearch’s 5TGM1 line has been luciferase-enabled to permit monitoring of growth in orthotopic sites such as the bone marrow by bioluminescent imaging […]

Approaches for Preclinical Evaluation of Ovarian Cancer

As many patients with ovarian cancer develop peritoneal ascites, one standard preclinical method is to deliver these cell lines intraperitoneally (IP) to mimic this disease state. With our luciferase expressing lines we are able to track and monitor disease establishment and progression with BLI and report out quantitative measurements of […]

A549 – A Model for Non-Small Cell Lung Cancer

At MI Bioresearch we have been using A549 as a model of NSCLC for more than 10 years. We have run numerous studies in the subcutaneous setting with a number of standard agents. Above are some examples of response to paclitaxel (Figure 1) and docetaxel, bevacizumab and the combination (Figure […]

MDA-MB-231-luc-D3H2LN: A Valuable Model for Triple-Negative Breast Cancer Research

Fig 3:  MDA-MB-231-luc-D3H2LN Mammary Fat Pad Orthotopic Implant – Lymph Nodes MI Bioresearch has also validated MDA-MB-231-luc-D3H2LN as a metastatic bone model following an intracardiac injection. The MDA-MB-231-luc-D3H2LN cells naturally hone to the bone. Utilizing bioluminescence imaging will ensure that the injections are successful and that treatment groups can be […]

Evaluation of the Immune Response Following Treatment with Anti-CTLA-4 Antibody, Radiation Therapy, or the Combination in Murine Model of Breast Cancer

Breast cancers are considered poorly immunogenic tumors, however, several approaches utilizing immunotherapies are being undertaken in the clinic to evaluate their potential for improving outcomes. Radiation therapy (RT) is a highly utilized clinical treatment modality in breast cancer. Radiation is known to modify the tumor microenvironment, induce cytokines and chemokines, and has been shown to […]

Comparison of Bioluminescence and MR Imaging to Evaluate Orthotopic Glioma Models

Glioblastoma multiforme (GBM) (also called glioblastoma) is a fast-growing glioma that develops from star-shaped glial cells (astrocytes and oligodendrocytes) that support the health of the nerve cells within the brain. These tumors are usually highly malignant because the cells reproduce quickly and they are supported by a large network of blood vessels. GBM is the […]

Get Glowing Results From Your Cell Lines – With Luciferase

Since different cell types use different promoters to express genes, a variety of promoters including EF1 alpha, CMV, UbC, and MSCV can be used. Also, for high-efficiency gene delivery, the pseudotype of the virus can be modified to VSV-G or MLV. If you are interested in luc-enabling your cell lines, contact […]

GL261: Syngeneic Murine Glioma Model

GL261 is one of the most frequently used syngeneic murine glioma models available. We capitalize on our state-of-the-art imaging capabilities to further interrogate the pharmacology of this model by utilizing a GL261 cell line that expresses luciferase (GL261-luc2, Caliper Life Sciences). This allows for longitudinal, in vivo visualization of the […]

Old Methods for a New Therapy — Imaging Gene Delivery

The promise of gene based therapies is stronger than ever.  Testament to this is the strides being taken in several areas; including mRNA based delivery and RNA interference.1 These successes are driving “new” applications for an “old” in vivo imaging assay, bioluminescence imaging (BLI).  BLI is based on detection of a reporter gene/protein (traditionally firefly […]

MV(4;11): A Model of Human AML (acute myeloid leukemia)

Acute myeloid leukemia (AML) is a malignant disorder of the progenitor cells in myeloid hematopoiesis and represents a genetically heterogeneous cancer. The onset of AML is thought to require cooperation between active proliferation and defects in myeloid differentiation, which often results in chromosomal translocation (Gilliland et al., 2004). The annual incidence of AML is ~1.8 per […]